Assessment of Heterotopic Ossification of Elbow Joint in Relation of Serum Uric Acid.

NCT03925688 | Completed

• 1 other identifier: I2019001071
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Heterotopic ossification (HO) is a common complication after surgical repair of elbow trauma. Uric acid is the end-product of purine metabolism that has any physiological and pathogenic potential functions. However, the relationship of HO and uric acid has not been explored up to now. This study aimed to assess the relationship of HO and uric acid. The investigators retrospectively reviewed the demographics of participants who undergone the surgery for elbow trauma in our hospital between January 2012 and December 2018. One hundred participants included in our study. The participants were divided into two groups by the existing HO or not. The serum uric acid between both groups were compared by using the independent samples student T tests.

Conditions

Heterotopic Ossification

Keywords

heterotopic ossification; serum uric acid，; elbow joint

Outcome Measures

Primary Outcomes (1)

• serum uric acid value

  The serum uric acid was measured by standard equipment in the laboratory

  the outcome of serum uric acid can acquire within half a day.

Study Arms (2)

without heterotopic ossification

There had not existed radiographic evidences of heterotopic ossification.

with heterotopic ossification

There had existed radiographic evidences of heterotopic ossification or formatted ectopic lamellar bone.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The population came from The Second Affiliated Hospital of Zhejiang University.

You may qualify if:

• Have a previous history of elbow joint fracture or dislocation that conform to its manifestations and signs. And it is diagnosed by X-ray test. HO must accord with the relative diagnostic criteria5 and have imaging evidences of heterotopic ossification.
• Have complete clinical and imaging dates.
• The age\>18 and no gender limitation.
• The patient is being a relatively stable physical and mental state without acute injection or diseases.

You may not qualify if:

• Have a history of diabetes mellitus or impaired blood glucose, metabolic syndrome and gout or renal dysfunction (creatinine ≥ 1.5 mg/dL) that apparently influence glucose, lipid and protein metabolic of the body.
• Have a history of taking drugs that can influence uric acid metabolic including gout suppressant, diuretic, small-dose aspirin (75\~300mg/d) or large-dose aspirin (\>3g/d), anti-tuberculosis drugs, immunosuppressor, nicotinic acid and anti-tumor drugs such as cyclophosphamide and so on.

Sponsors & Collaborators

• Second Affiliated Hospital, School of Medicine, Zhejiang University: lead

Study Sites (1)

Institutional Review Board of The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Location

MeSH Terms

Conditions

Ossification, Heterotopic

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Jian'an Wang, Ph.D

  Zhejiang University

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 21, 2019
• First Posted: April 24, 2019
• Study Start: March 13, 2019
• Primary Completion: April 1, 2019
• Study Completion: April 10, 2019
• Last Updated: April 25, 2019

Record last verified: 2019-04

Locations

CN (1)